We are in regular contact, Madam Chair, with the FDA, and their approach is very similar to the Canadian approach. They require companies to notify them. When they are notified, they take steps similar to what we've been doing through this emergency, which is expediting review. They reach out to foreign jurisdictions; I personally wrote to the EMA, FDA, and other jurisdictions seeking alternate supply, etc.,
When shortages are brought to our attention, absolutely, we will continue to respond with the best interests of patients first and foremost in our mind.